Purchase Order 75N91021P00110

<p>The National Cancer Institute awarded a purchase order to Creative Biolabs Inc. for antibody laboratory testing valued at $25,000, dated September 11, 2020, with completion by December 20, 2020. Work is performed at East Yaphank, New York under firm fixed-price terms. No set-aside applies.</p>

<p>The National Cancer Institute awarded a purchase order to Creative Biolabs Inc. for $19,800.00 in lab testing services, effective September 16, 2020, with completion targeted for December 20, 2020. Work is performed in East Yaphank, New York under firm fixed-price terms. No small business set-aside applies to this order.</p>

<p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $23,040.00 on May 20, 2020. The order procures a monoclonal antibody to detect the protein product of the gene 2810474O19RIK for use in Western blots and immunohistochemistry, supporting an ongoing research project initiated in 2014. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of December 19, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation on February 11, 2020, for drugs and biologicals with a ceiling value of $15,081.95. Place of performance is Grand Island, New York. The order is firm fixed price with an ultimate completion date of March 31, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Abcam Inc. for $16,000 on December 30, 2019, for antibodies, with performance in Cambridge, Massachusetts and a completion date of January 29, 2020. No set-aside applied. Firm fixed price.</p>

This is a $112,658 firm fixed-price purchase order contract awarded by the National Cancer Institute (NCI) to Creative Biolabs Inc., a biotechnology and pharmaceutical services company located in Shirley, New York. The contract is for specialized nanobody affinity maturation services using phage display library construction and selection, specifically targeting an anti-human BCMA nanobody for multiple myeloma applications. The objective is to deliver five affinity-optimized nanobody sequences...

This is a $19,980.00 firm fixed price purchase order awarded by the Department of Health and Human Services' National Institutes of Health, National Cancer Institute to Creative Biolabs Inc. for laboratory testing services. The contract has a period of performance from May 15, 2024 to July 10, 2024 and does not have a set-aside designation. Creative Biolabs Inc. is a for-profit organization that specializes in providing custom biotechnology and pharmaceutical services to support federal...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Creative Biolabs Inc. for $22,500.00 on October 29, 2020. Work is performed in East Yaphank, New York. The order calls for identification of the glucocorticoid receptor and its isoforms in different primary immune and non-immune cells through peptide synthesis, immunization, cell fusion, hybridoma screening, subcloning, hybridoma clone stabilization, and monoclonal antibody production. The...

<p>The National Cancer Institute awarded a purchase order to Bioivt, LLC for $24,750.00 on August 3, 2020, for laboratory testing services. Work is performed in Westbury, New York. The order carries a firm fixed price and no set-aside designation. Performance concludes November 30, 2020.</p>

The National Cancer Institute awarded a $17,064.17 firm fixed price contract to Genscript USA Inc. under a Blanket Purchase Agreement (BPA) call for the production of three custom antibodies and associated proteins required for antibody production. The award was made on November 18, 2019, with an ultimate completion date of January 3, 2025. The contract was processed to de-obligate expiring FY20 funding lines in accordance with NIH Office of Administrative Law and Management (OALM) Communication...